Jasper Therapeutics develops briquilimab, an antibody for mast cell driven diseases such as chronic urticaria and asthma. JSPR reports earnings on Mon, Nov 9, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 12 | Piper Sandler | Initiated | Buy |
Seasonality
How JSPR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
Whale Options Flow
90DNo whale options trades in JSPR in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether JSPR is in one of them and how their past JSPR trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered JSPR in an article yet. Here's the latest on the wider market.
About Jasper Therapeutics
Jasper Therapeutics is a biotechnology company based in Redwood City, California. It is developing briquilimab, an antibody designed to block a signal that mast cells need to survive. The company is testing the drug in diseases driven by mast cells, including chronic urticaria, a skin condition, and asthma. Its intended patients are adults living with these conditions, and it is also looking at other mast cell diseases for possible future development.
- Headquarters
- Redwood City, CA